370 related articles for article (PubMed ID: 12419748)
21. S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer.
Kim MK; Lee KH; Jang BI; Kim TN; Eun JR; Bae SH; Ryoo HM; Lee SA; Hyun MS
Jpn J Clin Oncol; 2009 Jan; 39(1):49-53. PubMed ID: 19060295
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer.
Song H; Han B; Park CK; Kim JH; Jeon JY; Kim IG; Kim HJ; Jung JY; Kim JH; Kwon JH; Jang G; Kim HY; Kim HS; Choi DR; Zang DY
Cancer Chemother Pharmacol; 2013 Oct; 72(4):845-52. PubMed ID: 23978987
[TBL] [Abstract][Full Text] [Related]
23. Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer.
Shoji H; Morizane C; Sakamoto Y; Kondo S; Ueno H; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M; Okusaka T
Jpn J Clin Oncol; 2016 Feb; 46(2):132-7. PubMed ID: 26685318
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of gemcitabine, UFT and leucovorin in patients with advanced pancreatic cancer.
Kim TW; Kang HJ; Ahn JH; Lee K; Chang HM; Kang YK; Lee JS
Acta Oncol; 2002; 41(7-8):689-94. PubMed ID: 14651215
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma.
Scheithauer W; Kornek GV; Raderer M; Hejna M; Valencak J; Miholic J; Kovats E; Lang F; Funovics J; Bareck E; Depisch D
Br J Cancer; 1999 Aug; 80(11):1797-802. PubMed ID: 10468299
[TBL] [Abstract][Full Text] [Related]
26. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
Kulke MH; Tempero MA; Niedzwiecki D; Hollis DR; Kindler HL; Cusnir M; Enzinger PC; Gorsch SM; Goldberg RM; Mayer RJ
J Clin Oncol; 2009 Nov; 27(33):5506-12. PubMed ID: 19858396
[TBL] [Abstract][Full Text] [Related]
27. Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer.
Rauch DP; Maurer CA; Aebi S; Pampallona S; Friess H; Ludwig CU; Büchler MW; Borner MM
Oncology; 2001; 60(1):43-8. PubMed ID: 11150907
[TBL] [Abstract][Full Text] [Related]
28. Fixed dose rate infusion of gemcitabine with oral doxifluridine and leucovorin for advanced unresectable pancreatic cancer: a phase II study.
Kim H; Park JH; Shin SJ; Kim MJ; Bang SJ; Park NH; Nah YW; Nam CW; Joo KR; Min YJ
Chemotherapy; 2008; 54(1):54-62. PubMed ID: 18073472
[TBL] [Abstract][Full Text] [Related]
29. A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer.
Childs HA; Spencer SA; Raben D; Bonner JA; Newsome J; Robert F
Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):939-44. PubMed ID: 10863063
[TBL] [Abstract][Full Text] [Related]
30. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E
Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797
[TBL] [Abstract][Full Text] [Related]
31. [Multicenter phase II study of pre-administered uracil/tegafur (UFT) plus gemcitabine for unresectable/recurrent pancreatic cancer].
Nakamori S; Endo W; Ozato H; Shibata T; Takeda Y; Tohno K; Hasuike Y; Masutani S; Morimoto T; Doki Y; Mori M; Monden M
Gan To Kagaku Ryoho; 2011 May; 38(5):789-92. PubMed ID: 21566438
[TBL] [Abstract][Full Text] [Related]
32. Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial.
Yang TS; Wang CH; Hsieh RK; Chen JS; Fung MC
Ann Oncol; 2002 Nov; 13(11):1771-8. PubMed ID: 12419750
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer.
Feliu J; Vicent JM; García-Girón C; Constela M; Fonseca E; Aparicio J; Lomas M; Antón-Aparicio L; Dorta FJ; Gonzalez-Baron M;
Br J Cancer; 2004 Nov; 91(10):1758-62. PubMed ID: 15505621
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.
Ko AH; Dito E; Schillinger B; Venook AP; Bergsland EK; Tempero MA
J Clin Oncol; 2006 Jan; 24(3):379-85. PubMed ID: 16344320
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of gemcitabine and UFT modulated by leucovorin in patients with advanced pancreatic carcinoma. The ONCOPAZ Cooperative Group.
Feliu J; López Alvarez MP; Jaraiz MA; Constenla M; Vicent JM; Belón J; López Gómez L; de Castro J; Dorta J; González Barón M
Cancer; 2000 Oct; 89(8):1706-13. PubMed ID: 11042564
[TBL] [Abstract][Full Text] [Related]
36. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.
Boeck S; Hoehler T; Seipelt G; Mahlberg R; Wein A; Hochhaus A; Boeck HP; Schmid B; Kettner E; Stauch M; Lordick F; Ko Y; Geissler M; Schoppmeyer K; Kojouharoff G; Golf A; Neugebauer S; Heinemann V
Ann Oncol; 2008 Feb; 19(2):340-7. PubMed ID: 17962204
[TBL] [Abstract][Full Text] [Related]
37. [Phase I/II study of combination chemotherapy with gemcitabine and UFT for advanced pancreatic cancer in a multi-center trial].
Sumii T; Funakoshi A; Mizumoto K; Tanaka M; Arita Y; Ito T; Yamaguchi H; Ueki T; Sakai T; Miyahara T; Muranaka T; Igarashi H; Shinozaki H; Eriguchi N
Gan To Kagaku Ryoho; 2008 Apr; 35(4):603-6. PubMed ID: 18408428
[TBL] [Abstract][Full Text] [Related]
38. Activity of raltitrexed and gemcitabine in advanced pancreatic cancer.
Kralidis E; Aebi S; Friess H; Büchler MW; Borner MM
Ann Oncol; 2003 Apr; 14(4):574-9. PubMed ID: 12649104
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of triplet chemotherapy using Tegafur-Uracil, Vinorelbine, Gemcitabine for advanced non-small cell lung cancer.
Minomo S; Asami K; Okishio K; Kawaguchi T; Fujita Y; Takata S; Tamura A; Saitou R; Atagi S
Anticancer Res; 2013 Mar; 33(3):1163-7. PubMed ID: 23482797
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study.
Mani S; Kugler JW; Sciortino DF; Garcia JC; Ansari RH; Humerickhouse R; Michelassi F; Posner MC; Shulman KL; Schilsky RL; List M; Vokes EE; Benner S
Ann Oncol; 1998 Sep; 9(9):1035-7. PubMed ID: 9818081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
